Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Daily Top 10 COVID-19 papers DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM

Tuberculosis

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 214 articles: HTML format

Single Articles

May 2020
1. LI Y, Dong W, Lan T, Fan J, et al
   Distribution of linezolid in tuberculosis lesions in patients with spinal multidrug-resistant tuberculosis.
   Antimicrob Agents Chemother. 2020 May 4. pii: AAC.00450.
   PubMed     Abstract available
   
   
   
2. KIM HY, Srivastava S, Kumar Ak H, Marais BJ, et al
   Optimal dose or optimal exposure? Consideration for linezolid in tuberculosis treatment.
   Antimicrob Agents Chemother. 2020 May 4. pii: AAC.00287.
   PubMed     Abstract available
   
   
   
3. DIACON AH, De Jager VR, Dawson R, Narunsky K, et al
   Reply to Kim et al., "Optimal Dose or Optimal Exposure? Consideration for Linezolid in Tuberculosis Treatment".
   Antimicrob Agents Chemother. 2020 May 4. pii: AAC.00709.
   PubMed     Abstract available
   
   
   April 2020
4. PIETERMAN ED, Sarink MJ, Sala C, Cole ST, et al
   Advanced quantification methods to improve the 18b dormancy model for assessing the activity of tuberculosis drugs in vitro.
   Antimicrob Agents Chemother. 2020 Apr 27. pii: AAC.00280.
   PubMed     Abstract available
   
   
   
5. NARMANDAKH E, Tumenbayar O, Borolzoi T, Erkhembayar B, et al
   Genetic Mutations Associated with Isoniazid Resistance in Mycobacterium tuberculosis in Mongolia.
   Antimicrob Agents Chemother. 2020 Apr 20. pii: AAC.00537.
   PubMed     Abstract available
   
   
   March 2020
6. HARIGUCHI N, Chen X, Hayashi Y, Kawano Y, et al
   OPC-167832, a novel carbostyril derivative with potent anti-tuberculosis activity as a DprE1 inhibitor.
   Antimicrob Agents Chemother. 2020 Mar 30. pii: AAC.02020.
   PubMed     Abstract available
   
   
   
7. SEKAGGYA-WILTSHIRE C, Chirehwa M, Musaazi J, von Braun A, et al
   Erratum for Sekaggya-Wiltshire et al., "Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?"
   Antimicrob Agents Chemother. 2020;64.
   PubMed    
   
   
   
8. ENKIRCH T, Werngren J, Groenheit R, Alm E, et al
   Systematic review of whole genome sequencing data to predict phenotypic drug resistance and susceptibility in Swedish Mycobacterium tuberculosis isolates 2016-2018.
   Antimicrob Agents Chemother. 2020 Mar 2. pii: AAC.02550.
   PubMed     Abstract available
   
   
   February 2020
9. RABIE H, Tikiso T, Lee J, Fairlie L, et al
   Abacavir exposure in children co-treated for tuberculosis with rifampicin and super-boosted lopinavir-ritonavir.
   Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.01923.
   PubMed     Abstract available
   
   
   
10. WALSH KF, McAulay K, Lee MH, Vilbrun SC, et al
    Early bactericidal activity trial of nitazoxanide for pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2020 Feb 18. pii: AAC.01956.
    PubMed     Abstract available
    
    
    
11. GENGENBACHER M, Zimmerman MD, Sarathy JP, Kaya F, et al
    Tissue distribution of doxycycline in animal models of tuberculosis.
    Antimicrob Agents Chemother. 2020 Feb 10. pii: AAC.02479.
    PubMed     Abstract available
    
    
    January 2020
12. KEMPKER RR, Alghamdi WA, Al-Shaer MH, Burch G, et al
    Correction for Kempker et al., "A Pharmacology Perspective on Simultaneous Tuberculosis and Hepatitis C Treatment".
    Antimicrob Agents Chemother. 2020;64.
    PubMed    
    
    
    
13. DIACON AH, De Jager VR, Dawson R, Narunsky K, et al
    Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2020 Jan 27. pii: AAC.02012.
    PubMed     Abstract available
    
    
    
14. MTHIYANE T, Millard J, Adamson J, Balakrishna Y, et al
    N-acetyltransferase 2 genotypes amongst Zulu Speaking South Africans and isoniazid/N-acetyl-isoniazid pharmacokinetics during anti-tuberculosis treatment.
    Antimicrob Agents Chemother. 2020 Jan 21. pii: AAC.02376.
    PubMed     Abstract available
    
    
    
15. ZHANG N, Strydom N, Tyagi S, Soni H, et al
    Mechanistic Modeling of Mycobacterium tuberculosis Infection in Murine Models for Drug and Vaccine Efficacy Studies.
    Antimicrob Agents Chemother. 2020 Jan 6. pii: AAC.01727.
    PubMed     Abstract available
    
    
    
16. JING W, Zong Z, Tang B, Wang J, et al
    Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.
    Antimicrob Agents Chemother. 2020 Jan 6. pii: AAC.01736.
    PubMed     Abstract available
    
    
    December 2019
17. BJUGARD NYBERG H, Draper HR, Garcia-Prats AJ, Thee S, et al
    Population pharmacokinetics and dosing of ethionamide in children with tuberculosis.
    Antimicrob Agents Chemother. 2019 Dec 23. pii: AAC.01984.
    PubMed     Abstract available
    
    
    
18. ELINGS W, Gaur A, Blok AJ, Timmer M, et al
    beta-Lactamase of Mycobacterium tuberculosis shows dynamics in the active site that increase upon inhibitor binding.
    Antimicrob Agents Chemother. 2019 Dec 23. pii: AAC.02025.
    PubMed     Abstract available
    
    
    
19. ABDELWAHAB MT, Leisegang R, Dooley KE, Mathad JS, et al
    Population Pharmacokinetics of Isoniazid, Pyrazinamide, and Ethambutol in South African Pregnant Women with Tuberculosis and HIV.
    Antimicrob Agents Chemother. 2019 Dec 16. pii: AAC.01978.
    PubMed     Abstract available
    
    
    November 2019
20. SUNDELL J, Bienvenu E, Birgersson S, Abelo A, et al
    Population pharmacokinetics and pharmacogenetics of ethambutol in adult patients co-infected with tuberculosis and HIV.
    Antimicrob Agents Chemother. 2019 Nov 11. pii: AAC.01583.
    PubMed     Abstract available
    
    
    October 2019
21. DONNELLAN S, Aljayyoussi G, Moyo E, Ardrey A, et al
    Intracellular pharmacodynamic modelling (PDi) is predictive of the clinical activity of fluoroquinolones against Tuberculosis.
    Antimicrob Agents Chemother. 2019 Oct 14. pii: AAC.00989.
    PubMed     Abstract available
    
    
    
22. KEMPKER RR, Alghamdi WA, Al-Shaer MH, Burch G, et al
    A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment.
    Antimicrob Agents Chemother. 2019 Oct 7. pii: AAC.01215.
    PubMed     Abstract available
    
    
    September 2019
23. LYONS MA
    Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients.
    Antimicrob Agents Chemother. 2019 Sep 30. pii: AAC.00732.
    PubMed     Abstract available
    
    
    
24. CARRIGY NB, Larsen SE, Reese V, Pecor T, et al
    Prophylaxis of Mycobacterium tuberculosis H37Rv Infection in a Preclinical Mouse Model via Inhalation of Nebulized Bacteriophage D29.
    Antimicrob Agents Chemother. 2019 Sep 16. pii: AAC.00871.
    PubMed     Abstract available
    
    
    
25. SOMMER R, Cole ST
    Monitoring Tuberculosis Drug Activity in Live Animals by Near-Infrared Fluorescence Imaging.
    Antimicrob Agents Chemother. 2019 Sep 16. pii: AAC.01280.
    PubMed     Abstract available
    
    
    
26. HENDON-DUNN CL, Pertinez H, Marriott AAN, Hatch K, et al
    Re-growth of Mycobacterium tuberculosis populations exposed to antibiotic combinations is due to the presence of isoniazid and not bacterial growth rate.
    Antimicrob Agents Chemother. 2019 Sep 16. pii: AAC.00570.
    PubMed     Abstract available
    
    
    
27. JO KW, Kim M, Kim YJ, Lee HK, et al
    Early discontinuation of ethambutol in pulmonary tuberculosis treatment based on results of the GenoType MTBDRplus assay: A prospective, multicenter, non-inferiority randomized trial in South Korea.
    Antimicrob Agents Chemother. 2019 Sep 16. pii: AAC.00980.
    PubMed     Abstract available
    
    
    
28. YADAV R, Saini A, Agarwal P, Kapoor P, et al
    A rare D94F change in gyrA gene of multi-drug resistant Mycobacterium tuberculosis possibly contributing to an unfavorable treatment outcome.
    Antimicrob Agents Chemother. 2019 Sep 9. pii: AAC.01312.
    PubMed     Abstract available
    
    
    
29. RICHARDS JP, Cai W, Zill NA, Zhang W, et al
    Adaptation of Mycobacterium tuberculosis to biofilm growth is genetically linked to drug tolerance.
    Antimicrob Agents Chemother. 2019 Sep 9. pii: AAC.01213.
    PubMed     Abstract available
    
    
    
30. MURASE LS, de Souza JVP, Meneguello JE, Seixas FAV, et al
    Possible binding of piperine in Mycobacterium tuberculosis RNA-polymerase and rifampicin synergism.
    Antimicrob Agents Chemother. 2019 Sep 3. pii: AAC.02520.
    PubMed     Abstract available
    
    
    
31. DEMARCO VP, Ordonez AA, Klunk M, Prideaux B, et al
    Erratum for DeMarco et al., "Determination of [(11)C]Rifampin Pharmacokinetics within Mycobacterium tuberculosis-Infected Mice by Using Dynamic Positron Emission Tomography Bioimaging".
    Antimicrob Agents Chemother. 2019;63.
    PubMed    
    
    
    August 2019
32. SALINGER DH, Nedelman JR, Mendel C, Spigelman M, et al
    Daily Dosing for Bedaquiline in Patients with Tuberculosis.
    Antimicrob Agents Chemother. 2019 Aug 26. pii: AAC.00463.
    PubMed     Abstract available
    
    
    
33. TANNER L, Evans JC, Seldon R, Jordaan A, et al
    In vitro efficacies, ADME, and pharmacokinetic properties of phenoxazine derivatives active against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2019 Aug 19. pii: AAC.01010.
    PubMed     Abstract available
    
    
    
34. XIAO S, Guo H, Weiner WS, Maddox C, et al
    Revisiting the beta-lactams for tuberculosis therapy: a compound-compound synthetic lethality approach.
    Antimicrob Agents Chemother. 2019 Aug 19. pii: AAC.01319.
    PubMed     Abstract available
    
    
    
35. WANG Q, Modongo C, Allender C, Engelthaler DM, et al
    Utility of targeted, amplicon-based deep sequencing to detect resistance to first-line tuberculosis drugs in Botswana.
    Antimicrob Agents Chemother. 2019 Aug 12. pii: AAC.00982.
    PubMed     Abstract available
    
    
    
36. PARK Y, Ahn YM, Jonnala S, Oh S, et al
    Inhibition of CorA dependent Magnesium Homeostasis is cidal in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2019 Aug 5. pii: AAC.01006.
    PubMed     Abstract available
    
    
    July 2019
37. LI H, Salinger DH, Everitt D, Li M, et al
    Long-Term Effects on QT prolongation of Pretomanid, Alone and in Combinations, in Patients with Tuberculosis.
    Antimicrob Agents Chemother. 2019 Jul 29. pii: AAC.00445.
    PubMed     Abstract available
    
    
    
38. SARATHY JP, Ragunathan P, Shin J, Cooper CB, et al
    TBAJ-876 retains Bedaquiline's activity against subunit c and of Mycobacterium tuberculosis F-ATP synthase.
    Antimicrob Agents Chemother. 2019 Jul 29. pii: AAC.01191.
    PubMed     Abstract available
    
    
    
39. KORYCKA-MACHALA M, Viljoen A, Pawelczyk J, Borowka P, et al
    1H-benzo[d]imidazole derivatives affect MmpL3 in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2019 Jul 22. pii: AAC.00441.
    PubMed     Abstract available
    
    
    
40. KIDWAI S, Bouzeyen R, Chakraborti S, Khare N, et al
    NU-6027 inhibits growth of Mycobacterium tuberculosis by targeting Protein Kinase D and Protein Kinase G.
    Antimicrob Agents Chemother. 2019 Jul 8. pii: AAC.00996.
    PubMed     Abstract available
    
    
    
41. GHODOUSI A, Rizvi AH, Baloch AQ, Ghafoor A, et al
    Acquisition of cross-resistance to Bedaquiline and Clofazimine following treatment for Tuberculosis in Pakistan.
    Antimicrob Agents Chemother. 2019 Jul 1. pii: AAC.00915.
    PubMed     Abstract available
    
    
    June 2019
42. REHBERG N, Omeje E, Ebada SS, van Geelen L, et al
    3-O-Methyl-alkylgallates inhibit fatty acid desaturation in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2019 Jun 17. pii: AAC.00136.
    PubMed     Abstract available
    
    
    
43. TENERO D, Derimanov G, Carlton A, Tonkyn J, et al
    First time in human (FTIH) study and prediction of early bactericidal activity for GSK3036656, a potent Leucyl - tRNA synthetase inhibitor for tuberculosis treatment.
    Antimicrob Agents Chemother. 2019 Jun 10. pii: AAC.00240.
    PubMed     Abstract available
    
    
    
44. MCNEIL MB, Cook GM
    Utilization of CRISPR interference to validate MmpL3 as a drug target in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2019 Jun 3. pii: AAC.00629.
    PubMed     Abstract available
    
    
    
45. O'DONNELL MR, Larsen MH, Brown TS, Jain P, et al
    Erratum for O'Donnell et al., "Early Detection of Emergent Extensively Drug-Resistant Tuberculosis by Flow Cytometry-Based Phenotyping and Whole-Genome Sequencing".
    Antimicrob Agents Chemother. 2019;63.
    PubMed    
    
    
    May 2019
46. SUVICHAPANICH S, Wattanapokayakit S, Mushiroda T, Yanai H, et al
    Genome-Wide Association Study Confirming the Association of NAT2 with Susceptibility to Anti-tuberculosis Drug-Induced Liver Injury in Thai Patients.
    Antimicrob Agents Chemother. 2019 May 20. pii: AAC.02692.
    PubMed     Abstract available
    
    
    
47. SEIFERT M, Capparelli E, Catanzaro DG, Rodwell TC, et al
    Using Mycobacterium tuberculosis single nucleotide polymorphisms to predict fluoroquinolone treatment response.
    Antimicrob Agents Chemother. 2019 May 13. pii: AAC.00076.
    PubMed     Abstract available
    
    
    
48. ZHANG Y, Zhu H, Fu L, Wang B, et al
    Identifying regimens containing a new drug candidate TBI-166 against Mycobacterium tuberculosis in vitro and in vivo.
    Antimicrob Agents Chemother. 2019 May 6. pii: AAC.02496.
    PubMed     Abstract available
    
    
    
49. AL-SHAER MH, Alghamdi WA, Alsultan A, An G, et al
    Fluoroquinolones in drug-resistant tuberculosis: culture conversion and pharmacokinetic/pharmacodynamic target attainment to guide dose selection.
    Antimicrob Agents Chemother. 2019 May 6. pii: AAC.00279.
    PubMed     Abstract available
    
    
    
50. MALIK AA, Brooks MB, Siddiqui S, Fuad J, et al
    Pharmacokinetics of Levofloxacin in Children Treated for Exposure to Drug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2019;63.
    PubMed     Abstract available
    
    
    
51. GHIMIRE S, Maharjan B, Jongedijk EM, Kosterink JGW, et al
    Evaluation of Saliva as a Potential Alternative Sampling Matrix for Therapeutic Drug Monitoring of Levofloxacin in Patients with Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2019;63.
    PubMed     Abstract available
    
    
    April 2019
52. VAN DEN ELSEN SHJ, Sturkenboom MGG, Akkerman OW, Manika K, et al
    Limited sampling strategies using linear regression and the Bayesian approach for therapeutic drug monitoring of moxifloxacin in tuberculosis patients.
    Antimicrob Agents Chemother. 2019 Apr 22. pii: AAC.00384.
    PubMed     Abstract available
    
    
    
53. GHODOUSI A, Tagliani E, Karunaratne E, Niemann S, et al
    Isoniazid resistance in Mycobacterium tuberculosis is a heterogeneous phenotype comprised of overlapping MIC distributions with different underlying resistance mechanisms.
    Antimicrob Agents Chemother. 2019 Apr 22. pii: AAC.00092.
    PubMed     Abstract available
    
    
    
54. IACOBINO A, Giannoni F, Pardini M, Piccaro G, et al
    The combination rifampin-nitazoxanide, but not rifampin-isoniazid-pyrazinamide-ethambutol, kills dormant Mycobacterium tuberculosis in hypoxia at neutral pH.
    Antimicrob Agents Chemother. 2019 Apr 22. pii: AAC.00273.
    PubMed     Abstract available
    
    
    
55. LUN S, Tasneen R, Chaira T, Stec J, et al
    Advancing the therapeutic potential of indoleamides for tuberculosis.
    Antimicrob Agents Chemother. 2019 Apr 22. pii: AAC.00343.
    PubMed     Abstract available
    
    
    
56. LOISEAU C, Brites D, Moser I, Coll F, et al
    Revised interpretation of the Hain Lifescience GenoType MTBC to differentiate Mycobacterium canettii and members of the M. tuberculosis complex.
    Antimicrob Agents Chemother. 2019 Apr 8. pii: AAC.00159.
    PubMed     Abstract available
    
    
    
57. BERUBE BJ, Russell D, Castro L, Choi SR, et al
    Novel MenA inhibitors are bactericidal against Mycobacterium tuberculosis and synergize with electron-transport chain inhibitors.
    Antimicrob Agents Chemother. 2019 Apr 8. pii: AAC.02661.
    PubMed     Abstract available
    
    
    
58. RANJAN R, Srivastava A, Bharti R, Roy T, et al
    Preclinical development of inhalable D-cycloserine and ethionamide to overcome pharmacokinetic interaction and enhance efficacy against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2019 Apr 8. pii: AAC.00099.
    PubMed     Abstract available
    
    
    
59. SAINI V, Ammerman NC, Chang YS, Tasneen R, et al
    Treatment-shortening effect of a novel regimen combining high-dose rifapentine and clofazimine in pathologically distinct mouse models of tuberculosis.
    Antimicrob Agents Chemother. 2019 Apr 1. pii: AAC.00388.
    PubMed     Abstract available
    
    
    March 2019
60. SEKAGGYA-WILTSHIRE C, Chirehwa M, Musaazi J, von Braun A, et al
    Low anti-tuberculosis drug concentrations in HIV-Tuberculosis co-infected adults with low body weight; is it time to update dosing guidelines?
    Antimicrob Agents Chemother. 2019 Mar 25. pii: AAC.02174.
    PubMed     Abstract available
    
    
    
61. SHI W, Cui P, Niu H, Zhang S, et al
    Introducing RpsA Point Mutations Delta438A and D123A into the Chromosome of M. tuberculosis Confirms their Role in Causing Resistance to Pyrazinamide.
    Antimicrob Agents Chemother. 2019 Mar 11. pii: AAC.02681.
    PubMed     Abstract available
    
    
    
62. ALGHAMDI WA, Alsultan A, Al-Shaer MH, An G, et al
    Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.
    Antimicrob Agents Chemother. 2019 Mar 11. pii: AAC.00055.
    PubMed     Abstract available
    
    
    
63. XU J, Li SY, Almeida DV, Tasneen R, et al
    Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis.
    Antimicrob Agents Chemother. 2019 Mar 4. pii: AAC.00021.
    PubMed     Abstract available
    
    
    
64. ISMAIL N, Peters RPH, Ismail NA, Omar SV, et al
    Clofazimine Exposure In Vitro Selects Efflux Pump Mutants and Bedaquiline Resistance.
    Antimicrob Agents Chemother. 2019;63.
    PubMed     Abstract available
    
    
    
65. MUSTAZZOLU A, Venturelli L, Dinarelli S, Brown K, et al
    A Rapid Unraveling of the Activity and Antibiotic Susceptibility of Mycobacteria.
    Antimicrob Agents Chemother. 2019;63.
    PubMed     Abstract available
    
    
    February 2019
66. SARATHY J, Blanc L, Alvarez-Cabrera N, O'Brien P, et al
    Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations.
    Antimicrob Agents Chemother. 2019 Feb 25. pii: AAC.02516.
    PubMed     Abstract available
    
    
    
67. XU J, Wang B, Fu L, Zhu H, et al
    In vitro and in vivo activities of the riminophenazine TBI-166 against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2019 Feb 19. pii: AAC.02155.
    PubMed     Abstract available
    
    
    
68. ROBERTSON GT, Ektnitphong VA, Scherman MS, McNeil MB, et al
    Efficacy and improved resistance potential of a cofactor-independent InhA inhibitor of Mycobacterium tuberculosis in a C3HeB/FeJ mouse model.
    Antimicrob Agents Chemother. 2019 Feb 11. pii: AAC.02071.
    PubMed     Abstract available
    
    
    
69. KAUSHIK A, Ammerman NC, Tyagi S, Saini V, et al
    Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection.
    Antimicrob Agents Chemother. 2019 Feb 11. pii: AAC.00007.
    PubMed     Abstract available
    
    
    
70. GYGLI SM, Keller PM, Ballif M, Blochliger N, et al
    Whole genome sequencing for drug resistance profile prediction in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2019 Feb 4. pii: AAC.02175.
    PubMed     Abstract available
    
    
    January 2019
71. O'DONNELL MR, Larsen MH, Brown TS, Jain P, et al
    Early detection of emergent extensively drug resistant tuberculosis (XDR-TB) by flow cytometry-based phenotyping and whole genome sequencing.
    Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.01834.
    PubMed     Abstract available
    
    
    
72. GARCIA-PRATS AJ, Purchase SE, Osman M, Draper HR, et al
    Pharmacokinetics, safety, and dosing of novel pediatric levofloxacin dispersible tablets in children with multidrug-resistant tuberculosis exposure.
    Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.01865.
    PubMed     Abstract available
    
    
    
73. RUIZ P, Causse M, Vaquero M, Casal M, et al
    In vitro activity of Tedizolid against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.01939.
    PubMed     Abstract available
    
    
    
74. FRANCIS J, Zvada SP, Denti P, Hatherill M, et al
    Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis.
    Antimicrob Agents Chemother. 2019 Jan 22. pii: AAC.01964.
    PubMed     Abstract available
    
    
    
75. WASSERMAN S, Denti P, Brust JCM, Tareq M, et al
    Linezolid pharmacokinetics in South African patients with drug resistant tuberculosis and a high prevalence of HIV co-infection.
    Antimicrob Agents Chemother. 2019 Jan 7. pii: AAC.02164.
    PubMed     Abstract available
    
    
    
76. GHAJAVAND H, Kargarpour Kamakoli M, Khanipour S, Pourazar Dizaji S, et al
    High Prevalence of Bedaquiline Resistance in Treatment-naive Tuberculosis Patients and Verapamil Effectiveness.
    Antimicrob Agents Chemother. 2019 Jan 2. pii: AAC.02530.
    PubMed     Abstract available
    
    
    
77. CHOULES MP, Wolf NM, Lee H, Anderson JR, et al
    Rufomycin Targets ClpC1 Proteolysis in Mycobacterium tuberculosis and M. abscessus.
    Antimicrob Agents Chemother. 2019 Jan 2. pii: AAC.02204.
    PubMed     Abstract available
    
    
    
78. KHALIL ZG, Hill TA, De Leon Rodriguez LM, Lohman RJ, et al
    Structure-activity relationships of wollamide cyclic hexapeptides with activity against drug-resistant and intracellular Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2019 Jan 2. pii: AAC.01773.
    PubMed     Abstract available
    
    
    
79. RICHARD M, Gutierrez AV, Viljoen A, Rodriguez-Rincon D, et al
    Mutations in the MAB_2299c TetR Regulator Confer Cross-Resistance to Clofazimine and Bedaquiline in Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2018;63.
    PubMed     Abstract available
    
    
    November 2018
80. DEKKERS BGJ, Akkerman OW, Alffenaar JWC
    The role of therapeutic drug monitoring in treatment optimization in tuberculosis and diabetes mellitus co-morbidity.
    Antimicrob Agents Chemother. 2018 Nov 19. pii: AAC.02074.
    PubMed     Abstract available
    
    
    
81. VAN RIJN SP, Zuur MA, Anthony R, Wilffert B, et al
    Evaluation of carbapenems for multi/extensive-drug resistant Mycobacterium tuberculosis treatment.
    Antimicrob Agents Chemother. 2018 Nov 19. pii: AAC.01489.
    PubMed     Abstract available
    
    
    
82. ANDRES S, Groschel MI, Hillemann D, Merker M, et al
    A diagnostic algorithm to investigate pyrazinamide and ethambutol resistance in rifampicin resistant Mycobacterium tuberculosis isolates in a low incidence setting.
    Antimicrob Agents Chemother. 2018 Nov 19. pii: AAC.01798.
    PubMed     Abstract available
    
    
    
83. MEIKLE V, Mossberg AK, Mitra A, Hakansson AP, et al
    A protein complex from human milk enhances the activity of antibiotics and drugs against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2018 Nov 12. pii: AAC.01846.
    PubMed     Abstract available
    
    
    
84. DE MIRANDA SILVA C, Hajihosseini A, Myrick J, Nole J, et al
    Effect of Moxifloxacin plus Pretomanid against Mycobacterium tuberculosis in Log-phase, Acid-phase and Non-Replicating-Persister (NRP)-phase in an in vitro Assay.
    Antimicrob Agents Chemother. 2018 Nov 5. pii: AAC.01695.
    PubMed     Abstract available
    
    
    
85. KWARA A, Yang H, Antwi S, Enimil A, et al
    Effect of rifampin/isoniazid-containing antituberculosis therapy on efavirenz pharmacokinetics in HIV-infected children aged 3 to 14 years old.
    Antimicrob Agents Chemother. 2018 Nov 5. pii: AAC.01657.
    PubMed     Abstract available
    
    
    
86. VILCHEZE C, Jacobs WR Jr
    Reply to Yew et al., "Vitamin C and Mycobacterium tuberculosis Persisters".
    Antimicrob Agents Chemother. 2018;62.
    PubMed    
    
    
    
87. YEW WW, Chang KC, Leung CC, Chan DP, et al
    Vitamin C and Mycobacterium tuberculosis Persisters.
    Antimicrob Agents Chemother. 2018;62.
    PubMed    
    
    
    October 2018
88. VAN DEN ELSEN SHJ, Sturkenboom MGG, van 't Boveneind-Vrubleuskaya N, Skrahina A, et al
    Population pharmacokinetic model and limited sampling strategies for personalized dosing of levofloxacin in tuberculosis patients.
    Antimicrob Agents Chemother. 2018 Oct 29. pii: AAC.01092.
    PubMed     Abstract available
    
    
    
89. MELIEF E, Bonnett SA, Zuniga ES, Parish T, et al
    Activation of 2,4-diaminoquinazoline in Mycobacterium tuberculosis by Rv3161c, a putative dioxygenase.
    Antimicrob Agents Chemother. 2018 Oct 15. pii: AAC.01505.
    PubMed     Abstract available
    
    
    
90. RYBNIKER J, Andreas Kohl T, Barilar I, Niemann S, et al
    No evidence for acquired mutations associated with cytochrome bc 1-inhibitor resistance in 13,559 clinical Mycobacterium tuberculosis complex isolates.
    Antimicrob Agents Chemother. 2018 Oct 15. pii: AAC.01317.
    PubMed     Abstract available
    
    
    September 2018
91. DOAN TN, Cao P, Emeto TI, McCaw JM, et al
    Predicting the Outcomes of New Short-Course Regimens for Multi-Drug Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modelling.
    Antimicrob Agents Chemother. 2018 Sep 24. pii: AAC.01487.
    PubMed     Abstract available
    
    
    
92. LOUIE A, Duncanson B, Myrick J, Maynard M, et al
    The Activity of Moxifloxacin against Acid-Phase and Non-Replicative Persister Phenotype Phase Mycobacterium tuberculosis in a Hollow Fiber Infection Model.
    Antimicrob Agents Chemother. 2018 Sep 24. pii: AAC.01470.
    PubMed     Abstract available
    
    
    
93. DIAN S, Yunivita V, Ganiem AR, Pramaesya T, et al
    A double-blinded randomised placebo-controlled phase II trial to evaluate high dose rifampicin for tuberculous meningitis: a dose finding study.
    Antimicrob Agents Chemother. 2018 Sep 17. pii: AAC.01014.
    PubMed     Abstract available
    
    
    August 2018
94. CAO R, Teskey G, Islamoglu H, Abrahem R, et al
    Characterizing the Effects of Glutathione as an Immunoadjuvant in the Treatment of Tuberculosis.
    Antimicrob Agents Chemother. 2018 Aug 20. pii: AAC.01132.
    PubMed     Abstract available
    
    
    
95. ALFARISI O, Mave V, Gaikwad S, Sahasrabudhe T, et al
    The effect of diabetes mellitus on the pharmacokinetics and pharmacodynamics of tuberculosis treatment.
    Antimicrob Agents Chemother. 2018 Aug 20. pii: AAC.01383.
    PubMed     Abstract available
    
    
    
96. LUPIEN A, Vocat A, Foo CS, Blattes E, et al
    An optimized background regimen for treatment of active tuberculosis with the next-generation benzothiazinone Macozinone (PBTZ169).
    Antimicrob Agents Chemother. 2018 Aug 20. pii: AAC.00840.
    PubMed     Abstract available
    
    
    
97. KANDLER JL, Mercante AD, Dalton TL, Ezewudo MN, et al
    Validation of novel Mycobacterium tuberculosis isoniazid resistance mutations not detectable by common molecular tests.
    Antimicrob Agents Chemother. 2018 Aug 6. pii: AAC.00974.
    PubMed     Abstract available
    
    
    
98. KOSER CU, Heyckendorf J, Andres S, Olaru ID, et al
    Reply to Dookie et al., "Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis".
    Antimicrob Agents Chemother. 2018;62.
    PubMed    
    
    
    
99. DOOKIE N, Naidoo K, Padayatchi N
    Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2018;62.
    PubMed    
    
    
    July 2018
100. JAGIELSKI T, Bakula Z, Brzostek A, Minias A, et al
     Characterization of mutations conferring resistance to rifampicin in Mycobacterium tuberculosis clinical strains.
     Antimicrob Agents Chemother. 2018 Jul 30. pii: AAC.01093.
     PubMed     Abstract available
     
     
     
101. PELOQUIN CA, Phillips PPJ, Mitnick CD, Eisenach K, et al
     Increased Doses Lead to Higher Drug Exposures of Levofloxacin for the Treatment of Tuberculosis.
     Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.00770.
     PubMed     Abstract available
     
     
     
102. PITON J, Vocat A, Lupien A, Foo C, et al
     Structure-based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2018 Jul 16. pii: AAC.00681.
     PubMed     Abstract available
     
     
     
103. PIETERMAN ED, Te Brake LHM, de Knegt GJ, van der Meijden A, et al
     Assessment of the additional value of verapamil to a moxifloxacin and linezolid combination regimen in a murine tuberculosis model.
     Antimicrob Agents Chemother. 2018 Jul 9. pii: AAC.01354.
     PubMed     Abstract available
     
     
     
104. AGUILAR-PEREZ C, Gracia B, Rodrigues L, Vitoria A, et al
     Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2018 Jul 9. pii: AAC.00359.
     PubMed     Abstract available
     
     
     June 2018
105. RANCOITA PMV, Cugnata F, Gibertoni Cruz AL, Borroni E, et al
     Validating a 14-drug microtitre plate containing bedaquiline and delamanid for large-scale research susceptibility testing of Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2018 Jun 25. pii: AAC.00344.
     PubMed     Abstract available
     
     
     
106. HORITA Y, Alsultan A, Kwara A, Antwi S, et al
     Evaluation of the Adequacy of WHO revised Dosages of the First-Line Anti-Tuberculosis Drugs in Children with Tuberculosis using Population Pharmacokinetic Modeling and Simulations.
     Antimicrob Agents Chemother. 2018 Jun 18. pii: AAC.00008.
     PubMed     Abstract available
     
     
     
107. DE MIRANDA SILVA C, Hajihosseini A, Myrick J, Nole J, et al
     Effect of Linezolid plus Bedaquiline against Mycobacterium tuberculosis in Log-Phase, Acid-Phase and Non-Replicating-Persister (NRP)-Phase in an In vitro Assay.
     Antimicrob Agents Chemother. 2018 Jun 4. pii: AAC.00856.
     PubMed     Abstract available
     
     
     
108. DRUSANO GL, Myrick J, Maynard M, Nole J, et al
     Linezolid Kills Acid Phase and Non-replicative Persister Phase Mycobacterium tuberculosis in a Hollow Fiber Infection Model.
     Antimicrob Agents Chemother. 2018 Jun 4. pii: AAC.00221.
     PubMed     Abstract available
     
     
     May 2018
109. ZONG Z, Jing W, Shi J, Wen S, et al
     Comparison of in vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in China.
     Antimicrob Agents Chemother. 2018 May 29. pii: AAC.00165.
     PubMed     Abstract available
     
     
     
110. SHOEN C, DeStefano M, Hafkin B, Cynamon M, et al
     In vitro and in vivo activity of contezolid (MRX-I) against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2018 May 21. pii: AAC.00493.
     PubMed     Abstract available
     
     
     
111. YEW WW, Chang KC, Chan DP
     Oxidative Stress and First-Line Antituberculosis Drug-Induced Hepatotoxicity.
     Antimicrob Agents Chemother. 2018 May 21. pii: AAC.02637.
     PubMed     Abstract available
     
     
     
112. AMMERMAN NC, Swanson RV, Bautista EM, Almeida DV, et al
     Impact of Clofazimine Dosing on Treatment-Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.
     Antimicrob Agents Chemother. 2018 May 7. pii: AAC.00636.
     PubMed     Abstract available
     
     
     
113. KAUFMANN SHE
     Indole Propionic Acid: a Small Molecule Links between Gut Microbiota and Tuberculosis.
     Antimicrob Agents Chemother. 2018;62.
     PubMed    
     
     
     April 2018
114. SHI W, Chen J, Zhang S, Zhang W, et al
     Identification of novel mutations in LprG (rv1411c), rv0521,rv3630, rv0010c, ppsC,cyp128 associated with pyrazinoic acid/pyrazinamide resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2018 Apr 23. pii: AAC.00430.
     PubMed     Abstract available
     
     
     
115. BOOT M, Commandeur S, Subudhi AK, Bahira M, et al
     Accelerating early anti-tuberculosis drug discovery by creating mycobacterial indicator strains that predict mode of action.
     Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00083.
     PubMed     Abstract available
     
     
     
116. ZHENG H, Williams JT, Coulson GB, Haiderer ER, et al
     HC2091 kills Mycobacterium tuberculosis by targeting the MmpL3 mycolic acid transporter.
     Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.02459.
     PubMed     Abstract available
     
     
     
117. LIU Y, Pertinez H, Davies GR, Gillespie SH, et al
     Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: Novel insights from the Cornell mouse model.
     Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00190.
     PubMed     Abstract available
     
     
     
118. LYONS MA
     Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients.
     Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.02359.
     PubMed     Abstract available
     
     
     
119. STEFAN MA, Ugur FS, Garcia GA
     SOURCE OF THE FITNESS DEFECT IN RIFAMYCIN-RESISTANT M. TUBERCULOSIS RNA POLYMERASE AND THE MECHANISM OF COMPENSATION BY MUTATIONS IN THE beta'-SUBUNIT.
     Antimicrob Agents Chemother. 2018 Apr 16. pii: AAC.00164.
     PubMed     Abstract available
     
     
     March 2018
120. ZIMENKOV D
     Mutation in luxR Family Transcriptional Regulator Rv0890c Is Not a Marker of Linezolid Resistance.
     Antimicrob Agents Chemother. 2018;62.
     PubMed    
     
     
     February 2018
121. GUPTA R, Felix CR, Akerman MP, Akerman KJ, et al
     Gold(III) macrocycles and chelates targeting Mycobacterium tuberculosis and Mycobacterium abscessus: evidence for inhibition of topoisomerase 1A.
     Antimicrob Agents Chemother. 2018 Feb 26. pii: AAC.01696.
     PubMed     Abstract available
     
     
     
122. CHEN C, Gardete S, Jansen RS, Shetty A, et al
     Verapamil targets membrane energetics in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.02107.
     PubMed     Abstract available
     
     
     
123. HEMANTH KUMAR AK, Kumar A, Kannan T, Bhatia R, et al
     Pharmacokinetics of second-line anti-tuberculosis drugs in children with multidrug-resistant tuberculosis in India.
     Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.02410.
     PubMed     Abstract available
     
     
     
124. WEINER M, Gelfond J, Johnson-Pais TL, Engle M, et al
     Elevated Plasma Moxifloxacin Concentrations and SLCO1B1 g.-11187G>A Polymorphism in Adults with Pulmonary Tuberculosis.
     Antimicrob Agents Chemother. 2018 Feb 20. pii: AAC.01802.
     PubMed     Abstract available
     
     
     
125. ZUUR MA, Ghimire S, Bolhuis MS, Wessels AMA, et al
     The Pharmacokinetics of 2000 mg Ertapenem in Tuberculosis Patients.
     Antimicrob Agents Chemother. 2018 Feb 12. pii: AAC.02250.
     PubMed     Abstract available
     
     
     
126. CHEN Y, Yuan Z, Shen X, Wu J, et al
     Time to Multidrug-Resistant Tuberculosis Treatment Initiation in Association with Treatment Outcomes in Shanghai, China.
     Antimicrob Agents Chemother. 2018 Feb 5. pii: AAC.02259.
     PubMed     Abstract available
     
     
     
127. SAO EMANI C, Williams MJ, Wiid I, Baker B, et al
     Compounds with potential activity against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2018 Feb 5. pii: AAC.02236.
     PubMed     Abstract available
     
     
     January 2018
128. WANG Q, Pang Y, Jing W, Liu Y, et al
     Clofazimine for Treatment of Pulmonary Extensively Drug-Resistant Tuberculosis in China.
     Antimicrob Agents Chemother. 2018 Jan 29. pii: AAC.02149.
     PubMed     Abstract available
     
     
     
129. HUO F, Luo J, Shi J, Zong Z, et al
     Increasing Prevalence of Rifampicin-Resistant Mycobacterium tuberculosis is Associated with the Transmission of Strains Harboring Compensatory Mutations in China: A 10-year Comparative Analysis.
     Antimicrob Agents Chemother. 2018 Jan 29. pii: AAC.02303.
     PubMed     Abstract available
     
     
     
130. DIJKSTRA JA, van der Laan T, Akkerman OW, Bolhuis MS, et al
     In vitro drug susceptibility of Mycobacterium tuberculosis for amikacin, kanamycin and capreomycin.
     Antimicrob Agents Chemother. 2018 Jan 8. pii: AAC.01724.
     PubMed     Abstract available
     
     
     
131. YU X, Zeng X, Shi W, Hu Y, et al
     The validation of Cycloserine efficacy in treatment of multidrug-resistant and extensively drug-resistant tuberculosis in Beijing, China.
     Antimicrob Agents Chemother. 2018 Jan 8. pii: AAC.01824.
     PubMed     Abstract available
     
     
     
132. VILCHEZE C, Kim J, Jacobs WR Jr
     Vitamin C potentiates the killing of Mycobacterium tuberculosis by the first-line tuberculosis drugs isoniazid and rifampicin in mice.
     Antimicrob Agents Chemother. 2018 Jan 3. pii: AAC.02165.
     PubMed     Abstract available
     
     
     
133. ALSULTAN A, Furin JJ, Du Bois J, van Brakel E, et al
     Erratum for Alsultan et al., "Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis".
     Antimicrob Agents Chemother. 2017;62.
     PubMed    
     
     
     December 2017
134. DOMPREH A, Tang X, Zhou J, Yang H, et al
     Effect of genetic variation of NAT2 on isoniazid, SLCO1B1, and CES2 on rifampin pharmacokinetics in Ghanaian children with tuberculosis.
     Antimicrob Agents Chemother. 2017 Dec 20. pii: AAC.02099.
     PubMed     Abstract available
     
     
     
135. AUNG WW, Ei PW, Nyunt WW, Htwe MM, et al
     Pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis clinical isolates in Myanmar.
     Antimicrob Agents Chemother. 2017 Dec 20. pii: AAC.01984.
     PubMed     Abstract available
     
     
     
136. SARATHY JP, Via LE, Weiner D, Blanc L, et al
     Extreme drug tolerance of Mycobacterium tuberculosis in caseum.
     Antimicrob Agents Chemother. 2017 Dec 4. pii: AAC.02266.
     PubMed     Abstract available
     
     
     
137. LEE H, Ahn S, Hwang NY, Jeon K, et al
     Limited Effect of Later-generation Fluoroquinolones in the Treatment of Ofloxacin-resistant and Moxifloxacin-susceptible Multidrug-resistant Tuberculosis.
     Antimicrob Agents Chemother. 2017 Dec 4. pii: AAC.01784.
     PubMed     Abstract available
     
     
     November 2017
138. DESHPANDE D, Srivastava S, Bendet P, Martin KR, et al
     On the antibacterial and sterilizing effect of benzylpenicillin in tuberculosis.
     Antimicrob Agents Chemother. 2017 Nov 27. pii: AAC.02232.
     PubMed     Abstract available
     
     
     
139. ABBADI BL, Villela AD, Rodrigues-Junior VS, Subtil FT, et al
     Revisiting activation of and the mechanism of resistance to the compound IQG-607 in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Nov 20. pii: AAC.02222.
     PubMed     Abstract available
     
     
     
140. DENTI P, Garcia-Prats AJ, Draper HR, Wiesner L, et al
     Levofloxacin population pharmacokinetics in South African children treated for multidrug-resistant tuberculosis.
     Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.01521.
     PubMed     Abstract available
     
     
     
141. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Tikiso T, et al
     Pharmacokinetics and drug-drug interactions of lopinavir/ritonavir administered with first and second-line antituberculosis drugs in HIV-infected children treated for multidrug-resistant tuberculosis.
     Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.00420.
     PubMed     Abstract available
     
     
     
142. HEYCKENDORF J, Andres S, Koser CU, Olaru ID, et al
     What is resistance? Impact of phenotypic versus molecular drug resistance testing on multi- and extensively drug-resistant tuberculosis therapy.
     Antimicrob Agents Chemother. 2017 Nov 13. pii: AAC.01550.
     PubMed     Abstract available
     
     
     October 2017
143. SUN Q, Xiao TY, Liu HC, Zhao XQ, et al
     Mutations within embCAB are associated with variable level of ethambutol resistance in Mycobacterium tuberculosis isolates from China.
     Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01279.
     PubMed     Abstract available
     
     
     
144. WILLBY MJ, Wijkander M, Havumaki J, Johnson K, et al
     Detection of Mycobacterium tuberculosis pncA mutations by the NIPRO GenoscholarPZA-TB II as compared to conventional sequencing.
     Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.01871.
     PubMed     Abstract available
     
     
     
145. BERUBE BJ, Parish T
     Combinations of respiratory chain inhibitors have enhanced bactericidal activity against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Oct 23. pii: AAC.01677.
     PubMed     Abstract available
     
     
     
146. GENESTET C, Ader F, Pichat C, Lina G, et al
     Combined Antibacterial Effect of Isoniazid and Rifampicin on Four Mycobacterium tuberculosis Strains: in Vitro Experiments and Response-Surface Modeling.
     Antimicrob Agents Chemother. 2017 Oct 23. pii: AAC.01413.
     PubMed     Abstract available
     
     
     
147. XU J, Tasneen R, Peloquin CA, Almeida DV, et al
     Verapamil increases the bioavailability and efficacy of bedaquiline but not clofazimine in a murine model of tuberculosis.
     Antimicrob Agents Chemother. 2017 Oct 16. pii: AAC.01692.
     PubMed     Abstract available
     
     
     
148. DE WELZEN L, Eldholm V, Maharaj K, Manson AL, et al
     Whole transcriptome and genomic analysis of extensively drug-resistant Mycobacterium tuberculosis clinical isolates identifies downregulation of ethA as a mechanism of ethionamide resistance.
     Antimicrob Agents Chemother. 2017 Oct 9. pii: AAC.01461.
     PubMed     Abstract available
     
     
     
149. NAKATANI Y, Opel-Reading HK, Merker M, Machado D, et al
     Role of alanine racemase mutations in Mycobacterium tuberculosis D-cycloserine resistance.
     Antimicrob Agents Chemother. 2017 Oct 2. pii: AAC.01575.
     PubMed     Abstract available
     
     
     September 2017
150. XU W, DeJesus MA, Rucker N, Engelhart CA, et al
     Chemical genomic interaction profiling reveals determinants of intrinsic antibiotic resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.01334.
     PubMed     Abstract available
     
     
     
151. KIDWAI S, Park CY, Mawatwal S, Tiwari P, et al
     The dual mechanism of action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.00969.
     PubMed     Abstract available
     
     
     
152. METCALFE JZ, Streicher E, Theron G, Colman RE, et al
     Mycobacterium tuberculosis subculture results in loss of potentially clinically relevant heteroresistance.
     Antimicrob Agents Chemother. 2017 Sep 11. pii: AAC.00888.
     PubMed     Abstract available
     
     
     
153. HUSZAR S, Singh V, Polcicova A, Barath P, et al
     N-Acetylglucosamine-1-phosphate transferase, WecA, as a validated drug target in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Sep 5. pii: AAC.01310.
     PubMed     Abstract available
     
     
     
154. PARK SW, Tasneen R, Converse PJ, Nuermberger EL, et al
     Immunodeficiency and Intermittent Dosing Promote Acquired Rifamycin Monoresistance in Murine Tuberculosis.
     Antimicrob Agents Chemother. 2017 Sep 5. pii: AAC.01502.
     PubMed     Abstract available
     
     
     
155. PELOQUIN CA, Velasquez GE, Lecca L, Calderon RI, et al
     Erratum for Peloquin et al., "Pharmacokinetic Evidence from the HIRIF Trial To Support Increased Doses of Rifampin for Tuberculosis".
     Antimicrob Agents Chemother. 2017;61.
     PubMed    
     
     
     
156. ARORA K, Ochoa-Montano B, Tsang PS, Blundell TL, et al
     Correction for Arora et al., "Respiratory Flexibility in Response to Inhibition of Cytochrome c Oxidase in Mycobacterium tuberculosis".
     Antimicrob Agents Chemother. 2017;61.
     PubMed    
     
     
     July 2017
157. MOOSA A, Lamprecht DA, Arora K, Barry CE 3rd, et al
     Susceptibility of Mycobacterium tuberculosis cytochrome bd oxidase mutants to compounds targeting the terminal respiratory oxidase, cytochrome c.
     Antimicrob Agents Chemother. 2017 Jul 31. pii: AAC.01338.
     PubMed     Abstract available
     
     
     
158. MCNEIL MB, Dennison D, Shelton C, Parish T, et al
     In vitro isolation and characterization of oxazolidinone resistant Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Jul 31. pii: AAC.01296.
     PubMed     Abstract available
     
     
     
159. ALSULTAN A, Furin JJ, Du Bois J, van Brakel E, et al
     Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis.
     Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.01066.
     PubMed     Abstract available
     
     
     
160. MOURIK BC, de Knegt GJ, Verbon A, Mouton JW, et al
     Assessment of bactericidal drug activity and treatment outcome in a mouse tuberculosis model using a clinical Beijing strain.
     Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.00696.
     PubMed     Abstract available
     
     
     
161. PANG Y, Zong Z, Huo F, Jing W, et al
     In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug -resistant tuberculosis from Beijing, China.
     Antimicrob Agents Chemother. 2017 Jul 24. pii: AAC.00900.
     PubMed     Abstract available
     
     
     
162. YANG SS, Hu YB, Wang XD, Gao YR, et al
     Deletion of sigB Causes Increased Sensitivity to para-Aminosalicylic Acid and Sulfamethoxazole in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Jul 17. pii: AAC.00551.
     PubMed     Abstract available
     
     
     
163. VAN RIJN SP, Srivastava S, Wessels MA, van Soolingen D, et al
     The sterilizing effect of ertapenem-clavulanate in a hollow fiber model of tuberculosis and implications on clinical dosing.
     Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.02039.
     PubMed     Abstract available
     
     
     
164. ZIMMERMAN M, Lestner J, Prideaux B, O'Brien P, et al
     Ethambutol partitioning in tuberculous pulmonary lesions explains its clinical efficacy.
     Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.00924.
     PubMed     Abstract available
     
     
     
165. PATEL N, O'Malley T, Zhang YK, Xia Y, et al
     A novel 6-benzyl ether benzoxaborole is active against Mycobacterium tuberculosis in vitro.
     Antimicrob Agents Chemother. 2017 Jul 3. pii: AAC.01205.
     PubMed     Abstract available
     
     
     June 2017
166. BABLISHVILI N, Tukvadze N, Shashkina E, Mathema B, et al
     The impact of gyrB and eis mutations in improving second-line drug resistance detection among Mycobacterium tuberculosis isolates from Georgia.
     Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.01921.
     PubMed     Abstract available
     
     
     
167. LI SY, Tasneen R, Tyagi S, Soni H, et al
     Bactericidal and sterilizing activity of a novel regimen with bedaquiline, pretomanid, moxifloxacin and pyrazinamide in a murine model of tuberculosis.
     Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.00913.
     PubMed     Abstract available
     
     
     
168. RAHMAN A, Ferdous SS, Ahmed S, Rahman SMM, et al
     Pyrazinamide susceptibility and pncA mutation profile of Mycobacterium tuberculosis among multi-drug resistant tuberculosis patients in Bangladesh.
     Antimicrob Agents Chemother. 2017 Jun 19. pii: AAC.00511.
     PubMed     Abstract available
     
     
     
169. CHIREHWA MT, McIlleron H, Rustomjee R, Mthiyane T, et al
     Pharmacokinetics of Pyrazinamide: optimising dosing regimens for drug-sensitive and -resistant tuberculosis.
     Antimicrob Agents Chemother. 2017 Jun 12. pii: AAC.00490.
     PubMed     Abstract available
     
     
     
170. RODRIGUES FELIX C, Gupta R, Geden S, Roberts J, et al
     Selective Killing Of Dormant Mycobacterium tuberculosis By Marine Natural Products.
     Antimicrob Agents Chemother. 2017 Jun 12. pii: AAC.00743.
     PubMed     Abstract available
     
     
     
171. ZHANG Y, Zhang J, Cui P, Zhang W, et al
     Identification of novel efflux proteins Rv0191, Rv3756c, Rv3008 and Rv1667c involved in pyrazinamide resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Jun 5. pii: AAC.00940.
     PubMed     Abstract available
     
     
     
172. SRIVASTAVA S, Magombedze G, Koeuth T, Sherman C, et al
     Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis.
     Antimicrob Agents Chemother. 2017 Jun 5. pii: AAC.00751.
     PubMed     Abstract available
     
     
     
173. FOFANA MO, Dowdy DW
     Reply to Anthony et al., "Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment".
     Antimicrob Agents Chemother. 2017;61.
     PubMed    
     
     
     
174. ANTHONY RM, Cynamon M, Hoffner S, Werngren J, et al
     Protecting Pyrazinamide, a Priority for Improving Outcomes in Multidrug-Resistant Tuberculosis Treatment.
     Antimicrob Agents Chemother. 2017;61.
     PubMed    
     
     
     May 2017
175. PELOQUIN CA, Velasquez GE, Lecca L, Calderon RI, et al
     Pharmacokinetic evidence to support increased doses of rifampin for tuberculosis: results from the HIRIF trial.
     Antimicrob Agents Chemother. 2017 May 30. pii: AAC.00038.
     PubMed     Abstract available
     
     
     
176. VAN'T BOVENEIND-VRUBLEUSKAYA N, Seuruk T, van Hateren K, van der Laan T, et al
     Pharmacokinetics of Levofloxacin in Multidrug- and Extensively Drug-Resistant Tuberculosis patients.
     Antimicrob Agents Chemother. 2017 May 15. pii: AAC.00343.
     PubMed     Abstract available
     
     
     
177. SLOAN DJ, McCallum AD, Schipani A, Egan D, et al
     Genetic determinants of the pharmacokinetic variability of rifampicin in Malawian adults with pulmonary tuberculosis.
     Antimicrob Agents Chemother. 2017 May 1. pii: AAC.00210.
     PubMed     Abstract available
     
     
     
178. MOREIRA W, Santhanakrishnan S, Ngan GJY, Low CB, et al
     Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome.
     Antimicrob Agents Chemother. 2017;61.
     PubMed     Abstract available
     
     
     April 2017
179. NJIRE M, Wang N, Wang B, Tan Y, et al
     Pyrazinoic Acid Inhibits a Bifunctional Enzyme in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.00070.
     PubMed     Abstract available
     
     
     
180. VISWANATHAN G, Yadav S, Raghunand TR
     Identification of mycobacterial genes involved in antibiotic sensitivity - Implications in the treatment of tuberculosis with beta-lactam containing regimens.
     Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.00425.
     PubMed     Abstract available
     
     
     
181. OLLIARO PL, Merle C, Mthiyane T, Bah B, et al
     Analysis of the effects on the QT interval of a gatifloxacin-containing regimen versus standard treatment of pulmonary tuberculosis.
     Antimicrob Agents Chemother. 2017 Apr 24. pii: AAC.01834.
     PubMed     Abstract available
     
     
     
182. DANELISHVILI L, Shulzhenko N, Chinison JJJ, Babrak L, et al
     Mycobacterium tuberculosis proteome response to anti-tuberculosis compounds reveals metabolic "escape" pathways that prolong bacterial survival.
     Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.00430.
     PubMed     Abstract available
     
     
     
183. JANG J, Kim R, Woo M, Jeong J, et al
     Efflux attenuates the anti-bacterial activity of Q203 in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.02637.
     PubMed     Abstract available
     
     
     
184. KEMPKER RR, Heinrichs MT, Nikolaishvili K, Sabulua I, et al
     Lung Tissue Concentrations of Pyrazinamide among Patients with Drug-Resistant Pulmonary Tuberculosis.
     Antimicrob Agents Chemother. 2017 Apr 3. pii: AAC.00226.
     PubMed     Abstract available
     
     
     
185. CHEN X, Hashizume H, Tomishige T, Nakamura I, et al
     Delamanid Kills Dormant Mycobacteria in Vitro and in the Guinea Pig Model of Tuberculosis.
     Antimicrob Agents Chemother. 2017 Apr 3. pii: AAC.02402.
     PubMed     Abstract available
     
     
     
186. VAN RIJN SP, Zuur MA, van Altena R, Akkerman OW, et al
     Pharmacokinetic Modeling and Limited Sampling Strategies Based on Healthy Volunteers for Monitoring of Ertapenem in Patients with Multidrug-Resistant Tuberculosis.
     Antimicrob Agents Chemother. 2017;61.
     PubMed     Abstract available
     
     
     March 2017
187. XU J, Wang B, Hu M, Huo F, et al
     Primary clofazimine and bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis.
     Antimicrob Agents Chemother. 2017 Mar 20. pii: AAC.00239.
     PubMed     Abstract available
     
     
     
188. ALSULTAN A, Savic R, Dooley KE, Weiner M, et al
     Population Pharmacokinetics of Pyrazinamide in Patients with Tuberculosis.
     Antimicrob Agents Chemother. 2017 Mar 13. pii: AAC.02625.
     PubMed     Abstract available
     
     
     
189. VELASQUEZ GE, Calderon RI, Mitnick CD, Becerra MC, et al
     Erratum for Velasquez et al., Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.
     Antimicrob Agents Chemother. 2017;61.
     PubMed    
     
     
     February 2017
190. RAMACHANDRAN G, Kumar AK, Chandrasekaran V, Kannan T, et al
     Factors influencing tuberculosis treatment outcome in adult patients treated with thrice-weekly regimens in India.
     Antimicrob Agents Chemother. 2017 Feb 27. pii: AAC.02464.
     PubMed     Abstract available
     
     
     
191. ROBERTS O, Khoo S, Owen A, Siccardi M, et al
     Interaction of Rifampicin and Darunavir/Ritonavir or Darunavir/Cobicistat In Vitro.
     Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.01776.
     PubMed     Abstract available
     
     
     
192. KAYIGIRE XA, Friedrich SO, van der Merwe L, Diacon AH, et al
     Acquisition of rifampin resistance in pulmonary tuberculosis.
     Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02220.
     PubMed     Abstract available
     
     
     
193. CHOI SR, Britigan BE, Narayanasamy P
     Ga(III) Nanoparticles Inhibit Growth of Both TB and HIV and Release of IL-6 and IL-8 in Co-Infected Macrophages.
     Antimicrob Agents Chemother. 2017 Feb 6. pii: AAC.02505.
     PubMed     Abstract available
     
     
     January 2017
194. AJILEYE A, Alvarez N, Merker M, Walker TM, et al
     Some synonymous and non-synonymous gyrA mutations in Mycobacterium tuberculosis lead to systematic false-resistance results to fluoroquinolones with the Hain GenoType MTBDRsl assays.
     Antimicrob Agents Chemother. 2017 Jan 30. pii: AAC.02169.
     PubMed     Abstract available
     
     
     
195. DE JAGER V, van der Merwe L, Venter A, Donald PR, et al
     Time trends in sputum mycobacterial load and 2-day bactericidal activity of INH-containing anti-tuberculosis therapies.
     Antimicrob Agents Chemother. 2017 Jan 30. pii: AAC.02088.
     PubMed     Abstract available
     
     
     
196. KUMAR P, Kaushik A, Bell D, Chauhan V, et al
     Mutation in an unannotated protein confers carbapenem resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Jan 9. pii: AAC.02234.
     PubMed     Abstract available
     
     
     
197. VAN ALTENA R, Dijkstra JA, van der Meer ME, Borjas Howard JF, et al
     Reduced chance of hearing loss associated with Therapeutic Drug Monitoring of Aminoglycosides in the treatment of Multidrug Resistant Tuberculosis.
     Antimicrob Agents Chemother. 2017 Jan 9. pii: AAC.01400.
     PubMed     Abstract available
     
     
     
198. SCHUMP MD, Fox DM, Bertozzi CR, Riley LW, et al
     Subcellular Partitioning and Intra-Macrophage Selectivity of Antimicrobial Compounds Against Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2017 Jan 4. pii: AAC.01639.
     PubMed     Abstract available
     
     
     December 2016
199. IACOBINO A, Piccaro G, Giannoni F, Mustazzolu A, et al
     Mycobacterium tuberculosis is selectively killed by rifampin and rifapentine in hypoxia at neutral pH.
     Antimicrob Agents Chemother. 2016 Dec 19. pii: AAC.02296.
     PubMed     Abstract available
     
     
     
200. FOFANA MO, Shrestha S, Knight GM, Cohen T, et al
     Role of pyrazinamide in the emergence of extensively drug-resistant tuberculosis: a multi-strain mathematical model.
     Antimicrob Agents Chemother. 2016 Dec 12. pii: AAC.00498.
     PubMed     Abstract available
     
     
     
201. PANG Y, Zhang Z, Wang Y, Wang S, et al
     Genotyping and prevalence of pyrazinamide- and moxifloxacin-resistant tuberculosis in China, 2000-2010: findings from the national survey data.
     Antimicrob Agents Chemother. 2016 Dec 5. pii: AAC.02170.
     PubMed     Abstract available
     
     
     November 2016
202. BROSSIER F, Pham A, Bernard C, Aubry A, et al
     Molecular investigation of resistance to second line injectable drugs in multidrug-resistant clinical isolates of Mycobacterium tuberculosis in France.
     Antimicrob Agents Chemother. 2016 Nov 28. pii: AAC.01299.
     PubMed     Abstract available
     
     
     
203. SEBASTIAN J, Swaminath S, Nair RR, Jakkala K, et al
     De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells formed against Antituberculosis Drugs In Vitro.
     Antimicrob Agents Chemother. 2016 Nov 28. pii: AAC.01343.
     PubMed     Abstract available
     
     
     
204. YEE M, Gopal P, Dick T
     Missense mutations in the unfoldase ClpC1 of the caseinolytic protease complex are associated with pyrazinamide resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2016 Nov 21. pii: AAC.02342.
     PubMed     Abstract available
     
     
     
205. ROSEN BC, Dillon NA, Peterson ND, Minato Y, et al
     Long-Chain Fatty Acyl-CoA Ligase FadD2 Mediates Intrinsic Pyrazinamide Resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.02130.
     PubMed     Abstract available
     
     
     
206. ANTWI S, Yang H, Enimil A, Sarfo AM, et al
     Pharmacokinetics of the First-line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with and without HIV Coinfection.
     Antimicrob Agents Chemother. 2016 Nov 14. pii: AAC.01701.
     PubMed     Abstract available
     
     
     
207. ALFFENAAR JC, Akkerman OW, van Hest R
     Statin Adjunctive Therapy for Tuberculosis Treatment.
     Antimicrob Agents Chemother. 2016;60:7004.
     PubMed    
     
     
     October 2016
208. PHOLWAT S, Stroup S, Heysell S, Ogarkov O, et al
     Eis C-14G and C-15G mutations do not confer kanamycin resistance in M. tuberculosis.
     Antimicrob Agents Chemother. 2016 Oct 10. pii: AAC.01775.
     PubMed     Abstract available
     
     
     September 2016
209. WANG X, Yang S, Gu J, Deng J, et al
     Mycobacterium tuberculosis arylamine N-acetyltransferase acetylates and thus inactivates para-aminosalicylic acid.
     Antimicrob Agents Chemother. 2016 Sep 26. pii: AAC.01312.
     PubMed     Abstract available
     
     
     
210. LI Y, Wang Y, Zhang Z, Gao H, et al
     Association between embB Codon 306 Mutations, Phenotypic Resistance Profiles and Genotypic Characterization in Clinical Mycobacterium tuberculosis Isolates from Hebei, China.
     Antimicrob Agents Chemother. 2016 Sep 26. pii: AAC.00532.
     PubMed     Abstract available
     
     
     
211. VELASQUEZ GE, Calderon RI, Mitnick CD, Becerra MC, et al
     Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in MDR-TB Patients.
     Antimicrob Agents Chemother. 2016 Sep 6. pii: AAC.00632.
     PubMed     Abstract available
     
     
     May 2016
212. NIGHTINGALE S, Chau TT, Fisher M, Nelson M, et al
     Efavirenz and metabolites in CSF; relationship with CYP2B6 c.516G>T genotype and perturbed blood-brain barrier due to tuberculous meningitis.
     Antimicrob Agents Chemother. 2016 May 9. pii: AAC.00280.
     PubMed     Abstract available
     
     
     January 2016
213. BEKKER A, Schaaf HS, Draper HR, van der Laan L, et al
     The pharmacokinetics of rifampicin, isoniazid, pyrazinamide and ethambutol in infants dosed at revised WHO-recommended treatment guidelines.
     Antimicrob Agents Chemother. 2016 Jan 25. pii: AAC.02600.
     PubMed     Abstract available
     
     
     November 2015
214. CHIREHWA MT, Rustomjee R, Mthiyane T, Onyebujoh P, et al
     Model-based evaluation of higher doses of rifampicin using a semi-mechanistic model incorporating auto-induction and saturation of hepatic extraction.
     Antimicrob Agents Chemother. 2015 Nov 9. pii: AAC.01830.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: